{"schema_version":"1","generated_at":"2026-10-29T19:35:08.640Z","data_as_of":"2026-10-27","url":"https://www.findmykol.com/kol/ecaterina-dumbrava","json_url":"https://www.findmykol.com/kol/ecaterina-dumbrava/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"ecaterina-dumbrava","name":"Ecaterina Dumbrava","credential":"MD","title":"Associate Professor, Investigational Cancer Therapeutics, Cancer Medicine","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Lung","therapeutic_areas":["Lung","Gastrointestinal"],"institution":"The University of Texas MD Anderson Cancer Center","institution_url":"https://www.findmykol.com/institution/the-university-of-texas-md-anderson-cancer-center","city":"Houston","state":"TX","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1881146868","orcid":"0000-0002-1959-0536","openalex":"A5113033878"},"summary":"Ecaterina Dumbrava is Associate Professor, Investigational Cancer Therapeutics, Cancer Medicine at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 394 publications with 2,688 citations (h-index 25); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.","overview":{"text":"Ecaterina Dumbrava, MD, is Associate Professor, Investigational Cancer Therapeutics, Cancer Medicine at The University of Texas MD Anderson Cancer Center. The public record shows 394 publications with 2,688 citations (h-index 25), centered on Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Immunotherapy and Immune Responses. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 4 companies.","bullets":["Most recent indexed publication: 2026 · Journal for immunotherapy of cancer","Top research focus: Cancer Immunotherapy and Biomarkers","11 registered trials on ClinicalTrials.gov","Open Payments reporting from 4 companies"],"generated_at":"2026-10-28"},"focus":{"indications":[{"label":"Breast Cancer","therapeutic_area":"Oncology","trials":4,"topics":0,"strength":12},{"label":"Lung Cancer (NSCLC/SCLC)","therapeutic_area":"Oncology","trials":2,"topics":1,"strength":7},{"label":"Pancreatic Cancer","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Hepatobiliary Cancer","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Small Cell Lung Carcinoma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Gastroesophageal Cancer","therapeutic_area":"Oncology","trials":1,"topics":1,"strength":4},{"label":"Multiple Sclerosis","therapeutic_area":"Neurology","trials":1,"topics":0,"strength":3},{"label":"Rheumatoid Arthritis","therapeutic_area":"Rheumatology/Immunology","trials":1,"topics":0,"strength":3},{"label":"Psoriasis / Psoriatic Arthritis","therapeutic_area":"Rheumatology/Immunology","trials":1,"topics":0,"strength":3},{"label":"Lupus (SLE)","therapeutic_area":"Rheumatology/Immunology","trials":1,"topics":0,"strength":3},{"label":"IBD (Crohn's / UC)","therapeutic_area":"Gastroenterology","trials":1,"topics":0,"strength":3},{"label":"Crohn Disease","therapeutic_area":"Gastroenterology","trials":1,"topics":0,"strength":3},{"label":"Colitis, Ulcerative","therapeutic_area":"Gastroenterology","trials":1,"topics":0,"strength":3},{"label":"ST Elevation Myocardial Infarction","therapeutic_area":"Cardiology","trials":1,"topics":0,"strength":3},{"label":"Autoimmune Diseases","therapeutic_area":"Rheumatology/Immunology","trials":1,"topics":0,"strength":3},{"label":"Scleroderma, Systemic","therapeutic_area":"Rheumatology/Immunology","trials":1,"topics":0,"strength":3},{"label":"Sjogren's Syndrome","therapeutic_area":"Ophthalmology","trials":1,"topics":0,"strength":3},{"label":"Ulcer","therapeutic_area":"Epidemiology","trials":1,"topics":0,"strength":3},{"label":"Myositis","therapeutic_area":"Neurology","trials":1,"topics":0,"strength":3},{"label":"Dermatomyositis","therapeutic_area":"Neurology","trials":1,"topics":0,"strength":3},{"label":"Colitis","therapeutic_area":"Gastroenterology","trials":1,"topics":0,"strength":3},{"label":"Erythema","therapeutic_area":"Dermatology","trials":1,"topics":0,"strength":3},{"label":"Neoplasm Metastasis","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Brain Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Colorectal Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Prostate Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Ovarian / Gynecologic Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Head & Neck Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Stomach Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Colonic Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Uterine Cervical Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Rectal Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Esophageal Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Endometrial Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Kidney Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Biliary Tract Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Melanoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Skin Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neoplasms, Germ Cell and Embryonal","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Cancer Immunotherapy and Biomarkers","Lung Cancer Treatments and Mutations","Immunotherapy and Immune Responses","HER2/EGFR in Cancer Research","Gastric Cancer Management and Outcomes"],"drugs_studied":{"total":8,"shown":3,"withheld":5,"rows":[{"name":"Trastuzumab","trials":1,"payments":0,"publications":3,"mentions":4},{"name":"Zanidatamab","trials":1,"payments":0,"publications":2,"mentions":3},{"name":"ALX148","trials":1,"payments":0,"publications":0,"mentions":1}]},"works_with":{"total":10,"shown":3,"withheld":7,"rows":[{"name":"M.D. Anderson Cancer Center","trials":5,"payments":0,"mentions":5},{"name":"AstraZeneca UK Limited","trials":0,"payments":3,"mentions":3},{"name":"Genentech, Inc.","trials":0,"payments":3,"mentions":3}]}},"scholarship":{"works_count":394,"cited_by_count":2688,"h_index":25,"i10_index":50,"pubmed_count":20,"latest_activity_year":2026,"source":"works"},"trials":{"count":11,"shown":3,"withheld":8,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT07436728","title":"A Study of TAK-505 in Adults With Solid Tumors","phase":"PHASE1/PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"Takeda","source_url":"https://clinicaltrials.gov/study/NCT07436728","trial_url":"https://www.findmykol.com/trial/NCT07436728"},{"nct":"NCT07164313","title":"A Study of ZW251 in Participants With Advanced Solid Tumors","phase":"PHASE1","status":"RECRUITING","role":"Investigator","sponsor":"Zymeworks BC Inc.","source_url":"https://clinicaltrials.gov/study/NCT07164313","trial_url":"https://www.findmykol.com/trial/NCT07164313"},{"nct":"NCT06760481","title":"Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)","phase":"PHASE1","status":"ACTIVE_NOT_RECRUITING","role":"Investigator","sponsor":"M.D. Anderson Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT06760481","trial_url":"https://www.findmykol.com/trial/NCT06760481"}],"source":"trials"},"payments":{"company_count":4,"program_years":{"first":2024,"last":2025},"rows_total":5,"shown":3,"withheld":2,"rows":[{"payer":"AstraZeneca UK Limited","program_year":2025,"amount_usd":2502.48,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1881146868"},{"payer":"Genentech, Inc.","program_year":2025,"amount_usd":137.27,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1881146868"},{"payer":"Stemline Therapeutics Inc.","program_year":2025,"amount_usd":117.3,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1881146868"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1881146868","source":"payments"},"prescribing":{"data_year":2022,"areas_total":2,"areas_shown":2,"areas":[{"area":"Nervous system","share_pct":57.1,"classes_total":1,"classes":[{"class":"Phenothiazine","setting":"prescribed","share_pct":57.1,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":14}]},{"area":"Metabolism & gastrointestinal","share_pct":42.9,"classes_total":1,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":42.9,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2022,"office_pct":0,"facility_pct":100},"source":"medicare"},"funding":{"award_count":0,"rows_total":0,"shown":0,"withheld":0,"rows":[],"source":"grants"},"congress":{"count":135,"years":{"first":2017,"last":2026},"societies":["AACR","ASCO","ESMO"],"shown":3,"withheld":132,"rows":[{"title":"Abstract 2967: Evolution of TOP1 variants under selective pressure from topoisomerase-based therapeutics.","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-2967","source_url":"https://doi.org/10.1158/1538-7445.am2026-2967","status":"verified"},{"title":"Abstract 356: Rezatapopt and KRAS inhibitors for the treatment of TP53 Y220C and KRAS mutant cancers.","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-356","source_url":"https://doi.org/10.1158/1538-7445.am2026-356","status":"verified"},{"title":"Abstract LB429: Impact of severe liver metastases on clinical response to immunotherapy in solid tumors","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"late_breaking_abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-lb429","source_url":"https://doi.org/10.1158/1538-7445.am2026-lb429","status":"verified"}],"source":"congress"},"publications":{"total":20,"shown":5,"withheld":15,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.","year":2026,"journal":"Journal for immunotherapy of cancer","types":["Journal Article","Clinical Trial, Phase I","Multicenter Study"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42705861/","status":"verified"},{"title":"Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors.","year":2026,"journal":"Cancer discovery","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41885383/","status":"verified"},{"title":"Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.","year":2026,"journal":"Future oncology (London, England)","types":["Journal Article","Clinical Trial Protocol"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41777164/","status":"verified"},{"title":"The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology.","year":2026,"journal":"Nature reviews. Clinical oncology","types":["Journal Article","Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41492079/","status":"verified"},{"title":"Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.","year":2026,"journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","types":["Journal Article","Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41283902/","status":"verified"}],"most_cited":{"total":394,"shown":5,"withheld":389,"rows":[{"title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials","year":2023,"cited_by_count":407,"type":"article","source_url":"https://doi.org/10.1038/s41591-022-02103-8"},{"title":"Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer","year":2018,"cited_by_count":349,"type":"review","source_url":"https://doi.org/10.1158/1078-0432.ccr-18-2275"},{"title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","year":2020,"cited_by_count":133,"type":"article","source_url":"https://doi.org/10.1136/jitc-2019-000347"},{"title":"Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification","year":2022,"cited_by_count":101,"type":"article","source_url":"https://doi.org/10.1200/jco.22.00830"},{"title":"First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation.","year":2022,"cited_by_count":83,"type":"conference-abstract","source_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.3003"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Funda Meric‐Bernstam","coauthored_works":248,"profile_url":"https://www.findmykol.com/kol/funda-meric-bernstam"},{"name":"Jordi Ahnert Rodon","coauthored_works":205},{"name":"Sarina Anne Piha-Paul","coauthored_works":193}],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/ecaterina-dumbrava-md","status":"provisional"}]},"mentions":{"total":1,"shown":1,"rows":[{"url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","platform":"other","status":"provisional"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":5,"shown":5,"rows":[{"value":"American Board of Internal Medicine (2025)","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"},{"value":"French Board of Medical Oncology (2014)","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"},{"value":"Romanian Board of Medical Oncology (2014)","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"},{"value":"MD, University of Medicine and Pharmacy \"Iuliu-Hatieganu\", Cluj-Napoca, Romania (General Medicine)","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"},{"value":"M.Sc., Health Biology-Oncology/Early Drug Development, Paris South University, Orsay","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"}]},"roles":{"total":6,"shown":3,"rows":[{"value":"Member of Editorial Review Board, Editorial Board of Journal of Immunotherapy and Precision Oncology (JIPO) (2023-present)","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"},{"value":"Associate Scientific Advisor, Science Translational Medicine (2020-2021)","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"},{"value":"Member, Society for Immunotherapy of Cancer (2019-present)","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"}]},"awards":{"total":3,"shown":3,"rows":[{"value":"K12 Paul Calabresi Advanced Scholar, NCI (2018)","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"},{"value":"ASCO Merit Award, American Society of Clinical Oncology (2017)","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"},{"value":"AACR Scholar-in-Training Award, American Association for Cancer Research (2017)","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"}]},"secondary_affiliations":{"total":6,"shown":3,"rows":[{"value":"Director, MD Anderson Molecular Tumor Board, The University of Texas MD Anderson Cancer Center","source_url":"https://orcid.org/0000-0002-1959-0536","status":"verified","collected_at":"2026-10-28"},{"value":"Director for Investigational Cancer Therapeutics/Phase 1, The University of Texas MD Anderson Cancer Center","source_url":"https://orcid.org/0000-0002-1959-0536","status":"verified","collected_at":"2026-10-28"},{"value":"Lead, ICT Inpatient Unit, The University of Texas MD Anderson Cancer Center","source_url":"https://orcid.org/0000-0002-1959-0536","status":"verified","collected_at":"2026-10-28"}]},"media":{"total":3,"shown":3,"rows":[{"value":"Interview, 2023: MDM2 Inhibition Marches on Across Cancer Settings","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"},{"value":"Interview, 2021: Can immunotherapy treat cancer in patients with autoimmune diseases?","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"},{"value":"Interview, 2020: Monoclonal antibodies and cancer treatment: What to know?","source_url":"https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html","status":"verified","collected_at":"2026-10-28"}]}},"similar":[{"name":"Hagop Kantarjian","slug":"hagop-kantarjian","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/hagop-kantarjian","json_url":"https://www.findmykol.com/kol/hagop-kantarjian/profile.json"},{"name":"Gabriel Hortobagyi","slug":"gabriel-hortobagyi","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gabriel-hortobagyi","json_url":"https://www.findmykol.com/kol/gabriel-hortobagyi/profile.json"},{"name":"Jaffer Ajani","slug":"jaffer-ajani","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jaffer-ajani","json_url":"https://www.findmykol.com/kol/jaffer-ajani/profile.json"},{"name":"Funda Meric-Bernstam","slug":"funda-meric-bernstam","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Surgery","url":"https://www.findmykol.com/kol/funda-meric-bernstam","json_url":"https://www.findmykol.com/kol/funda-meric-bernstam/profile.json"},{"name":"Pasi Janne","slug":"pasi-janne","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/pasi-janne","json_url":"https://www.findmykol.com/kol/pasi-janne/profile.json"},{"name":"Julie Brahmer","slug":"julie-brahmer","institution":"Johns Hopkins University School of Medicine","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/julie-brahmer","json_url":"https://www.findmykol.com/kol/julie-brahmer/profile.json"},{"name":"Enriqueta Felip","slug":"enriqueta-felip","institution":"Vall d'Hebron Institute of Oncology (VHIO)","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/enriqueta-felip","json_url":"https://www.findmykol.com/kol/enriqueta-felip/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":8,"payments":2,"congress":132,"publications":15,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-28"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-28"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2024 to 2025","collected_at":"2026-10-28"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2022},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-10-28"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-28"}},"methodology_url":"https://www.findmykol.com/about#methodology"}